Cidara Therapeutics — Investor Presentation (May 2024)
63 slides from Cidara Therapeutics's investor presentation, May 3, 2024
Slide 1: Corporate Presentation: May 2024
1 Corporate Presentation: May 2024 NASDAQ: CDTX
Slide 2: Forward-Looking Statements
2 Fo r w a rd - L o o k i n g S ta t e m e n t s T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 . The words “may,” “will,” “estimate,”
Slide 3: CD388 Reacquired from Janssen Pharmaceuticals
3 C D 3 8 8 Re a c q u i re d f ro m J a n s s e n P h a r m a c e u t i c a l s
Slide 4: Rezafungin Divested to Mundipharma
4 Re za f u n g i n D i v e s t e d t o M u n d i p h a r m a * Cost savings to be applied to advancing CD388 and other Cloudbreak development programs, including CBO421 $67M $61M Approximately $67M in clinical development and CMC costs over next three years Approximately $61M in forecasted obligati
Slide 5: The New Cidara – Cloudbreak Drug Fc Conjugate Programs
5 CLOUDBREAK T h e N e w C i d a ra – C l o u d b r e a k ® D r u g F c C o n j u g a t e ( D F C ) P ro g ra m s Program Indication Discovery Preclinical IND-enab. Phase 1 Phase 2 Viral Neuraminidase Prevention of Seasonal Influenza CD73 Solid Tumors, TNBC1 PD-1/ CD73 Solid Tumors CCR5 Solid Tumors
Slide 6: Cloudbreak DFCs: A Modular Platform With Broad Applications
6 C l o u d b re a k D F C s : A M o d u l a r P l a t fo r m W i t h B ro a d A p p l i c a t i o n s A c ro s s M u l t i p l e T h e ra p e u t i c A re a s DRUG Fc CONJUGATE (DFC) Small molecule Targeting Moiety (TM) All the strengths of mAbs with several potential advantages • Efficient targeti
Slide 7: DFCs May Improve Small Molecule Drug Potency and Safety
7 D F C s M ay I m p ro v e S m a l l M o l e c u l e D r u g Po t e n c y a n d S a fe t y DFC Target Cell Target Cell Cyp450s, intracellular proteins Multivalent target engagement increases potency, reduces resistance potential Unlike most small molecules, DFCs don’t enter cells, reducing off-targ
Slide 8: DFCs Have Reduced Potential for Off-Target Toxicity
8 % hERG inhibition @10mM SM 77 DFC < 5 D F C s H av e Re d u c e d Po t e n t i a l fo r O f f - Ta rg e t Tox i c i t y Many SM programs have failed to advance due to intracellular off-target toxicity (e.g., hepatotoxicity)* Cardiovascular toxicity due to hERG inhibition has impaired clinical deve
Slide 9: Cidara's Pipeline Targets Multiple Unmet Medical Needs
9 C i d a ra ’s P i p e l i n e Ta rg e t s M u l t i p l e U n m e t M e d i c a l N e e d s CLOUDBREAK ANTIVIRAL CLOUDBREAK ONCOLOGY
Slide 10: The Problem: A Universal Flu Vaccine Does Not Exist
10 I n f l u e n z a w o r l d w i d e d e a t h r a t e s > 6 5 0 , 0 0 0 p e r y e a r 2 T h e P ro b l e m : A “ U n i v e rs a l ” F l u Va c c i n e D o e s n o t E x i s t Low vaccine effectiveness General population (5-year flu season average) Immunocompromised ~40% 1 ~ 5% 4 Few viable progra
Slide 11: CD388 Development Data Confirm the Target Product Profile
11 C D 3 8 8 D e v e l o p m e n t D ata C o n f i r m t h e Ta rg e t P ro d u c t P ro f i l e ( T P P ) Single dose / ̴ 4-6 months Promising Phase 2a data CD388 Neuraminidase inhibitor (NAI) TM Potential for Universal protection Potential to protect high-risk groups Potential for prevention and t
Slide 12: Opportunity: First Universal Influenza Preventative
12 O p p o r t u n i t y : F i r s t “ U n i v e r s a l ” I n f l u e n z a P r e v e n t a t i v e • Reacquired Global Development and Commercial Rights from Janssen April’24 • Phase 2a results achieved safety, efficacy and PK objectives • Coverage of diverse panels of seasonal and pandemic strain
Slide 13: Comprehensive Global IP Protects CD388 Exclusivity
13 C o m p re h e n s i v e G l o b a l I P P ro t e c t s C D 3 8 8 E xc l u s i v i t y CD388 Zanamivir Dimer Linker DAR Fc Portfolio Highlights: • Global Portfolio Pending in 31 Jurisdictions • Eight Patent Families Directed to: − CD388 Composition of Matter* − Fc Construct Composition of Matter
Slide 14: CD388 Differentiated From Other Influenza Prophylactics
14 C D 3 8 8 I s D i f fe re n t i a t e d F ro m O t h e r I n f l u e n za P ro p hy l a c t i c s Companies in Space Modality Others3 Others3,4 / Others5 DFC (CD388) Stage of Development Spectrum Efficacy in High-Risk Populations Route of Administration Vaccines – strain specific (mRNA, conventio
Slide 15: CD388: Potential First Universal Influenza Preventative
15 C D 3 8 8 : Po t e n t i a l F i rs t “ U n i v e rs a l ” I n f l u e n za P re v e n tat i v e OST = Oseltamivir carboxylate; ZAN = Zanamivir; BXA = Baloxavir acid C D 3 8 8 r e t a i n s p o t e n t a n t i v i r a l a c t i v i t y a c r o s s d i v e r s e s e a s o n a l a n d h i g h p a t
Slide 16: Potential for Single Dose, Long-Acting Prevention in Lethal Models
16 100% survival across broad dose range Protection against body weight loss Po t e n t i a l fo r S i n g l e D o s e , L o n g - A c t i n g P re v e n t i o n i n L e t h a l M o d e l s Exposure selected for clinical development Survival1 Body Weight C D 3 8 8 h a s t h e p o t e n t i a l t o b
Slide 17: CD388 Retains In Vivo Activity Against NAI Resistant Strains
17 C D 3 8 8 R e t a i n s I n V i v o A c t i v i t y A g a i n s t H i g h l y N A I R e s i s t a n t S t r a i n s Strain Neuraminidase inhibition IC50 (nM) Protective dose (mg/kg) CD388 Zanamivir CD388 Zanamivir B/Laos/0080/2016 H134 (NAI-S) 7.44 2.61 0.3 1 B/Laos/0654/2016 H134N (NAI-R) 4.66 3
Slide 18: CD388 Reduces Viral Burden in Lung
18 Ve hi cle Os el ta m ivi r 5 0 m g/ kg CD 38 8 0. 1 m g/ kg CD 38 8 0. 3 m g/ kg CD 38 8 1 m g/ kg CD 38 8 3 m g/ kg Un in fe ct ed 103 104 105 106 107 108 P F U /g *** *** *** *** C D 3 8 8 Re d u c e s V i ra l B u rd e n i n L u n g BLQ Study Details: • Mouse adapted A/Puerto Rico/8/1934 (H1N1
Slide 19: CD388 Properties Enable Flexible Dosing Options
19 C D 3 8 8 P ro p e r t i e s E n a b l e F l ex i b l e D o s i n g O p t i o n s Bioavailability of multiple formulations highlights potential for SC dosing in oncology indications E q u i v a l e n t e f f i c a c y w h e t h e r d o s e d v i a I V , s u b c u t a n e o u s o r i n t r a m u s
Slide 20: CD388 Nonclinical Summary
20 C D 3 8 8 N o n c l i n i c a l S u m m a r y D a t a s u p p o r t p o t e n t i a l f o r s i n g l e d o s e “ u n i v e r s a l ” p r e v e n t i o n a n d t r e a t m e n t • Potent in-vitro and in-vivo activity against all tested seasonal and pandemic strains of influenza A and B, including
Slide 21: Objectives of Early Clinical Programs
21 O b j e c t i v e s o f Ea r l y C l i n i c a l P ro g ra m s Can CD388 be used for seasonal prophylaxis of influenza?Pharmacokinetics Is CD388 well-tolerated and amenable for prophylactic use?Safety Does CD388 exhibit activity against influenza in the respiratory tract of humans?Efficacy
Slide 22: Phase 1 and Phase 2a Clinical Studies
22 P h a s e 1 a n d P h a s e 2 a C l i n i c a l S t u d i e s A Phase 1, Randomized, Double-Blind, Single-Dose and Repeat Single Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects (63 su
Slide 23: CD388 Was Well-Tolerated
23 C D 3 8 8 Wa s We l l - To l e ra t e d fo r U p To 9 0 0 M G Dose FIH JBS HCS Total 50 mg 18 7 2 27 150 mg 18 7 28 53 450 mg 18 7 0 25 900 mg 9 0 0 9 All Doses 63 21 30 114 Number of participants that received one dose of CD388 in Phase 1 and Phase 2a studies (as of Aug 2023) FIH- First in Human
Slide 24: CD388 Demonstrated Efficacy in Phase 2a
24 Endpoint Placebo N=28 CD388 150 mg N=28 P-value qRT-PCR confirmed influenza infection * 14 (50%) 6 (21%) 0.0248 qRT-PCR confirmed symptomatic influenza infection ** 9 (32%) 4 (14%) 0.1023 qRT-PCR confirmed moderately to severe symptomatic influenza infection *** 7 (25%) 3 (11%) 0.1477 Primary end
Slide 25: Viral Culture Data Confirmed Efficacy Seen in Early Analyses
25 Mean – 95% Confidence interval *, * = mean. Placebo median = 0.50; CD388 150 mg median = 0.50 Mean VL from Viral Culture Peak Viral Load from Viral Culture Placebo CD388 150mg TreatmentVisit/Timepoint Placebo CD388 150 mg V i ra l C u l t u re D ata C o n f i r m e d Ef f i c a c y S e e n i n Ea
Slide 26: Phase 2b CD388 Influenza Prevention Study Planned in Fall 2024
26 P h a s e 2 b C D 3 8 8 I n f l u e n za P re v e n t i o n S t u d y P l a n n e d i n Fa l l 2 0 2 4 P h a s e 2 b D o u b l e - B l i n d R C T f o r t h e E f f i c a c y / S a f e t y o f C D 3 8 8 v s P l a c e b o i n t h e P r e v e n t i o n o f I n f l u e n z a • Study Design: Blinded,
Slide 27: CD388 Phase 2b Estimated Development Timeline
27 2024 2025 2026 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 C D 3 8 8 P h a s e 2 b E s t i m at e d D e v e l o p m e n t T i m e l i n e CD388 Phase 2B Study (n ~4,000) 2 Northern Hemisphere Flu Season Southern Hemisphere Flu Season* 1 Actual timelines may differ materially due to severity of flu season, rate of pa
Slide 28: CD388: A Potential Multi-Billion Dollar Market Opportunity
28 C D 3 8 8 : A Po t e n t i a l M u l t i - B i l l i o n D o l l a r M a r ke t O p p o r t u n i t y 1 Source: Influenza Global Flu market till 2032 (2023-2032 CAGR 11.07%). https://www.globenewswire.com/en/news-release/2024/03/05/2840453/0/en/Global-Influenza-Vaccine-Market-to-Attain-Valuation-
Slide 29: Benchmarks of Estimated Peak Sales for Selected Prophylactic Flu Programs
29 Estimated Peak Sales 2 Multi-billion dollar potential $5.6bn $5.2bn $2.9bn $3.9bn $5.9bn1 Modality DFC mRNA Vaccine mAb mRNA Vaccine Quadrivalent mod RNA Vaccine (mRNA vaccine) Quadrivalent Vaccine (egg and Cell based) Current Status Phase 2 Phase 2/3 Terminated Phase 2 Phase 3 Commercial Broker
Slide 30: Cidara's Pipeline Targets Multiple Unmet Medical Needs
30 C i d a ra ’s P i p e l i n e Ta rg e t s M u l t i p l e U n met M e d i ca l N e e d s CLOUDBREAK ANTIVIRAL CLOUDBREAK ONCOLOGY
Slide 31: Cloudbreak Oncology DFC Programs
31 C l o u d b re a k O n c o l o g y D F C P ro g ra m s CD73: CBO421 Development Candidate • Differentiated from existing SM and mAb CD73 inhibitors • Complete responders in combination with PD-1 inhibitors • Excellent safety and COGS PD-1/CD73 Discovery Program • Unique dual inhibitor of CD73 and
Slide 32: Cloudbreak Oncology DFC Programs
32 C l o u d b re a k O n c o l o g y D F C P ro g ra m s CD73: CBO421 Development Candidate • Differentiated from existing SM and mAb CD73 inhibitors • Complete responders in combination with PD-1 inhibitors • Excellent safety and COGS PD-1/CD73 Discovery Program • Unique dual inhibitor of CD73 and
Slide 33: Adenosine Is an Important Mediator of Tumor Immune Evasion
33 Rationale for CD73 • Adenosine creates an immune suppressive Tumor Microenvironment (TME) by reprogramming multiple immune cell classes • Dying tumor cells release ATP into the TME which subsequently gets converted into adenosine by CD73 • CD73 inhibitors are an ideal partner for chemotherapy Mas
Slide 34: CD73 Clinical Data To Date Has Been Disappointing
34 C D 7 3 C l i n i c a l D ata To D at e H a s B e e n D i s a p p o i n t i n g Therapy Drug Class Safety Profile Single agent activity Combination Efficacy Oleclumab (AstraZeneca) mAb Benign None1 With anti-PD-L1 in stage III NSCLC2: • ORR 30% (vs. 17.9%) • No additional CR’s achieved beyond PD-
Slide 35: Recent Phase 1b Data Supports CD73 as a Valid Target
35 Ph2 COAST trial in stage III NSCLC R e c e n t P h a s e 1 b D a t a S u p p o r t s C D 7 3 a s a Va l i d Ta r g e t : I m p r o v e d O v e r a l l S u r v i v a l C o m b i n i n g C D 7 3 I n h i b i t o r W i t h C h e m o t h e r a p y 1. Wainberg et al. GI ASCO 2024 poster https ://doi.or
Slide 36: CBO421 Emerging as a Differentiated CD73 Therapy
36 C B O 4 2 1 E m e rg i n g a s a D i f fe re n t i a t e d C D 7 3 T h e ra p y CBO421 CD73 ADO X AMP • Differentiated from existing SM and mAb CD73 inhibitors • Highly stable with excellent pharmaceutical properties • ~65 kDa (vs > 150 kDa for mAbs) – better tumor penetration • Inhibits both mem
Slide 37: CBO421 Exhibits Differentiated Preclinical Performance
37 C B O 4 2 1 E x h i b i t s D i f fe re n t i a t e d P re c l i n i c a l Pe r fo r m a n c e Differentiated from Existing Adenosine Pathway Inhibitors PBMC rescue assay (ATP) vs clinical stage adenosine pathway inhibitors Potent Anti-Tumor Activity as Monotherapy MC38 – murine colorectal carcin
Slide 38: CBO421 Exhibits Superior Tumor Penetration vs. mAbs
38 Tu m o r C o n t ro l : C B O 4 2 1 E x h i b i t s S u p e r i o r Tu m o r Pe n e t rat i o n v s . m A b s CD421 Oleclumab 0 50 100 150 200 250 300 0.0 0.1 0.2 0.3 0.4 CBO421 Relative Fluorescence Intensity Edge Center MDA-MB-231* Spheroids Study conducted by PhenoVista Biosciences MDA-MB-231
Slide 39: CBO421 Enhances Anti-tumor Activity of PD-1 Inhibitors
39 MC38 – murine colorectal carcinoma C B O 4 2 1 E n h a n c e s A n t i - t u m o r A c t i v i t y O f P D - 1 I n h i b i t o rs Study Arm % Responders2 Vehicle 0 CBO421 27 Anti-PD-11 47 CBO421 + Anti-PD-11 60 1. *RMP1-14 2. Defined as mice that demonstrate cessation of tumor growth or reduction
Slide 40: CBO421 Elicits Complete Responses with PD-1 Inhibitors
40 Survival (Day 62) Compounds dosed 2x weekly for 22 days Survivor rechallenge EMT6 tumor cells C B O 4 2 1 E l i c i t s C o m p l e t e Re s p o n s e s w i t h P D - 1 I n h i b i t o rs D+62 (re-challenge) Last dose (D+22) 40-day washout period Study start (D+0) D+73 EMT6 – murine mammary carci
Slide 41: Chemotherapy Creates a Feedback Loop That Can Overwhelm CD73 Inhibitors
41 CD73 expression increases in response to chemotherapy, creating a pro-tumorigenic environment1 • Small molecule CD73 inhibitors have no effect on CD73 levels, and can be overwhelmed by increasing ADO levels induced by chemotherapy • mAb CD73 inhibitors are limited by inferior catalytic inhibition
Slide 42: Low CBO421 Concentrations Rapidly Reduce CD73 Levels
42 ≥ 1 nM concentrations, CBO421 removes detectable cell anchored CD73 from the cancer cell surface L o w C B O 4 2 1 C o n c e n t rat i o n s R a p i d l y Re d u c e C D 7 3 L e v e l s o n C D 7 3 + T N B C C e l l s ( M DA - M B - 2 3 1 ) * 1 nMUntreated 0.001 nM 0.01 nM 0.1 nM *MDA-MB-231 cell
Slide 43: Receptor Internalization and Potent Catalytic Inhibition Position CBO421
43 Test article Target/Class Maximum % internalization EC50 [nM] CBO421 CD73/DFC 81 0.07 AB680* CD73/small molecule 0* NA Oleclumab# CD73/mAb 38 0.27 C o m b i n at i o n o f Re c e p t o r I n t e r n a l i za t i o n a n d Po t e n t C ata l y t i c I n h i b i t i o n Po s i t i o n s C B O 4 2 1
Slide 44: CBO421 Development for High Unmet Need TNBC Populations
44 Lacks ER, PR, and HER21: no targeted or hormonal therapies available C B O 4 2 1 D e v e l o p m e n t f o r H i g h U n m e t N e e d T N B C P o p u l a t i o n s L e v e ra g e s Po t e n t i a l B e n e f i t o f C D 7 3 / C h e m o C o m b i n a t i o n T h e ra p y Triple Negative Breast Ca
Slide 45: Planned First-in-Human Clinical Trials for CBO421
45 P l a n n e d F i rs t - i n - H u m a n C l i n i ca l Tr i a l s fo r C B O 4 2 1 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 IND Submission Phase 1 Study in Solid Tumors (including TNBC) GLP Toxicity Study (in-life complete)* Pre-clinical Clinical Actual timelines may differ materially due to timing of
Slide 46: Cloudbreak CD73/PD-1 Bispecific DFCs
46 C l o u d b re a k C D 7 3 / P D - 1 B i s p e c i f i c D F C s CD73: CBO421 Development Candidate • Differentiated from existing SM and mAb CD73 inhibitors • Complete responders in combination with PD-1 inhibitors • Excellent safety and COGS PD-1/CD73 Discovery Program • Unique dual inhibitor o
Slide 47: Potential First-in-Class PD-1/CD73 Inhibitor
47 Po t e n t i a l F i rs t - i n - C l a s s P D - 1 / C D 7 3 I n h i b i t o r D i s a b l e s Tw o M a j o r Tu m o r I m m u n e E s c a p e M e c h a n i s m s i n a S i n g l e M o l e c u l e CD73 inhibitor Killer T-cell PD-1 CD73 CD73 PD-1 inhibitor PD-L1 Cidara’s first multispecific DFC (
Slide 48: PD-1/CD73 DFC Potently Inhibits Both PD-1 and CD73 Receptors
48 CTP-PD-1 PD-1/CD73 DFC CD73 DFC P D - 1 / C D 7 3 D F C Po t e n t l y I n h i b i t s B o t h P D - 1 a n d C D 7 3 Re c e p t o rs CD73 inhibitor PD-1 Binding (IC50, nM) – 0.056 T-cell reactivation (EC50, nM) – 12 PD-1 Binding (IC50, nM) – 0.064 T-cell reactivation (EC50, nM) – 9 PD-1 inhibitor
Slide 49: PD-1/CD73 DFC Demonstrates Superior Tumor Growth Inhibition
49 P D - 1 / C D 7 3 D F C D e m o n st ra t e s S u p e r i o r Tu m o r G ro w t h I n h i b i t i o n v s M o n o t h e ra p i e s i n H u m a n i ze d Tu m o r M o d e l s Tumor Volume (MC38, hPD-L1), day 22 hPD-1/hPD-L1 C57BL/6 mice – 2X weekly dosing Tumor Volume (MC38, hPD-L1), day 22 hPD-1/h
Slide 50: PD-1/CD73 Improves Release of Immune Suppression
50 Dendritic cells (DCs) express CD73 and PD-L1/L2 P D - 1 / C D 7 3 I m p ro v e s Re l e a s e o f I m m u n e S u p p re s s i o n Do no r 1 P BM Cs Do no r 1 P BM Cs + D on or 2 D Cs 30 0µ M A M P CB O4 21 PD -1 D FC PD -1 /C D7 3 DF C 0 1000 2000 3000 IL -2 ( p g/ m L) ns * ** Do no r 1 P BM Cs
Slide 51: PD-1/CD73 DFC Demonstrates Robust Tumor Growth Inhibition
51 * ns * Tumor Volume (MC38, hPD-L1) hPD-1/hPD-L1 C57BL/6 mice – 2X weekly dosing Tumor Volume (MC38, hPD-L1) hPD-1/hPD-L1 C57BL/6 mice – 2X weekly dosing P D - 1 / C D 7 3 D F C D e m o n st ra t e s Ro b u st Tu m o r G ro w t h I n h i b i t i o n * ** ** P D - 1 / C D 7 3 D F C r e t a i n s s
Slide 52: Cidara's PD-1/CD73 DFC Is Differentiated
52 C i d a ra ’s P D - 1 / C D 7 3 D F C i s D i f fe re n t i a t e d Attribute PD-1/CD73 DFC AK131 Potential for differentiation with PD-1/CD73 DFC Size < 125 kDa > 200 kDa Superior tumor penetration, better potential for high concentration formulations Inhibition of CD73 catalytic activity Full P
Slide 53: PD-1/CD73 DFC Offers Advantages Over Cytotoxic ADCs and Bispecific mAbs
53 Attribute ADC Bispecific mAb DFC Advantage of DFC Example Sacituzumab Govitecan Enfortumab Vedotin PD-1/LAG3 PD-1-CTLA4 PD-1/CD73 PD-1/CD73 Size >150kDa > 200 kDa < 125 kDa Smaller size allows enhanced tumor penetration Cytotoxic component Yes No No No chemotherapy component allows enhanced safet
Slide 54: PD-1/CD73 Clinical Development Strategy
54 P D - 1 / C D 7 3 C l i n i c a l D e v e l o p m e n t S t ra t e g y – A F i rs t i n C l a s s O p p o r t u n i t y • Potential first-in-class, novel molecule: clinical trials historically enroll faster • Single infusion of multi-specific DFC vs. sequential infusions of 2 separate therapeutic
Slide 55: Cloudbreak CCR5 DFC Program
55 C l o u d b re a k C C R 5 D F C P ro g ra m CD73: CBO421 Development Candidate • Differentiated from existing SM and mAb CD73 inhibitors • Complete responders in combination with PD-1 inhibitors • Excellent safety and COGS PD-1/CD73 Discovery Program • Unique dual inhibitor of CD73 and PD-1 • Co
Slide 56: CCR5: Compelling Target That Drives Progression of Cancers
56 CCR5 signaling promotes immune cell migration to tumor, where they are “educated” in the TME to become immunosuppressive (e.g. TREGS, tumor-associated macrophages (M2-TAMs) Tumor cells “hijack” CCR5 signaling to induce tumor growth, angiogenesis, chemotherapy resistance CCR5-DFC CCR5 Antagonist X
Slide 57: CCR5 Is a Compelling Oncology Target
57 C C R 5 i s a C o m p e l l i n g O n c o l o g y Ta rg e t D e v e l o p m e n t c a n d i d a t e n o m i n a t i o n a n t i c i p a t e d i n m i d - 2 0 2 4 Acts as a “GPS” system that promotes metastatic disease and migration of immune suppressive cells to tumor1,2 • CCR5+ Circulating Tumor
Slide 58: Two Competitor CCR5 Programs with Known Liabilities
58 • Enhanced safety profile and compatibility with chemotherapy vs small molecule antagonists • Potential as a combination agent with SOC chemotherapy in TNBC • Potential for development of first in class multispecific therapies • Potential to develop for long-acting HIV retroviral therapy (with pa
Slide 59: CCR5 DFC Induces Tumor Reduction
59 First CCR5 targeting therapy designed for oncology V o lu m e ( m m 3 ) WT mice CCL5 KO mice C C R 5 D F C I n d u c e s Tu m o r Re d u c t i o n C o m m e n s u rat e W i t h a C C L 5 KO M o d e l i n C o l o re c ta l C a rc i n o m a p=0.0089 20 MPK 2X/week 1. Zhang et al. Cell Death and Dis
Slide 60: Cloudbreak Oncology DFC Programs
60 C l o u d b re a k O n c o l o g y D F C P ro g ra m s CD73: CBO421 Development Candidate • Differentiated from existing SM and mAb CD73 inhibitors • Complete responders in combination with PD-1 inhibitors • Excellent safety and COGS PD-1/CD73 Discovery Program • Unique dual inhibitor of CD73 and
Slide 61: Financial Overview
61 On April 24, 2024, the Company raised an additional $240 million in gross proceeds in a private placement led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners. Important Information December 31, 20231 Cash and Cash E
Slide 62: Capital Structure and Share Information
62 C a p i ta l S t r u c t u re a n d S h a re I n fo r m at i o n All shares in millions 12/31/23 1 (as filed 10-K) 4/24/24 Split -Adjusted (1:20)5 4/24/24 PIPE Financing (Split Adjusted 1:20)5 4/24/24 Pro-forma PIPE Financing & Reverse Split (1:20)5 Common Shares Outstanding 90,601,999 4,530,100
Slide 63: Thank You
63 Thank You May 2024 NASDAQ: CDTX
Cidara Therapeutics — Investor Presentation (May 2024) on 6ix